Glaukos Way Ahead Of The Glaucoma Competition By: Benzinga via Benzinga September 23, 2016 at 13:53 PM EDT Cantor Fitzgerald reiterated its Buy rating and $41 price target on Glaukos Corp (NYSE: GKOS) after the company reported efficacy data ... Read More >> Related Stocks: Glaukos Corp Novartis Ag ADR